1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol has been researched along with Alloxan Diabetes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avraham, Y; Berry, EM; Dagon, Y; Link, G; Mechoulam, R; Zolotarev, O | 1 |
1 other study(ies) available for 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol and Alloxan Diabetes
| Article | Year |
|---|---|
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells.
Topics: Animals; Brain; Cell Proliferation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Dronabinol; Female; Mice; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats | 2007 |